Evolent Health, Inc.
NYSE:EVHMedical - Healthcare Information Services
-$0.28 today
- Market cap
- $442.05M
- Beta
- 0.83
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.44
Volume 3.10M
Average 2.78M
EVH Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Evolent Health, Inc.NYSE: EVH
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 27M | — |
| FY2021 | 2021-12-31 | 0 | — |
Research & Development vs competitors
How EVH compares with its peers on the latest reported figures
- EVH's LTM Mar 2026 research & development of $0 is the 9th highest of the 11 companies compared; the peer median is $79.47M.
- Research & development amounts to 0.0% of revenue for EVH, versus a peer median of 25.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $260.36M | +37.3% | +39.3% | 363.4% | |
| LTM Dec 2025 | $223.39M | +26.2% | +32.9% | — | |
| LTM Mar 2026 | $129.68M | +5.2% | +71.4% | — | |
| LTM Mar 2026 | $128.82M | +9.2% | +14.8% | 161.5% | |
| LTM Mar 2026 | $106.4M | -7.7% | +7.7% | 12.8% | |
| LTM Mar 2026 | $52.54M | +7.4% | +4.8% | 16.9% | |
| LTM Mar 2026 | $52.16M | +6.9% | -8.2% | 80.9% | |
| LTM Mar 2026 | $35.88M | -3.0% | -25.6% | 34.9% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding EVH) | $79.47M | +7.2% | +11.3% | 25.9% | |
Competitors are the stored peer set for EVH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 907.96M | 1.35B | 1.96B | 2.55B | 1.88B |
| Cost of Revenue | 657.55M | 1.04B | 1.5B | 2.19B | 1.59B |
| Gross Profit | 250.41M | 316.58M | 460.47M | 367.35M | 284.03M |
| Gross Margin | 27.6% | 23.4% | 23.4% | 14.4% | 15.1% |
| Research & Development | 0 | 27M | 0 | 0 | 0 |
| Selling, General & Admin | 219.5M | 269.27M | 358.11M | 263.05M | 288.47M |
| Operating Expenses | 292.82M | 312.94M | 531.68M | 407.84M | 288.47M |
| Depreciation & Amortization | 60.04M | 90.25M | 123.42M | 123.17M | 115.85M |
| EBITDA | 55.66M | 43.75M | (24.79M) | 84.85M | (361.31M) |
| EBITDA Margin | 6.1% | 3.2% | -1.3% | 3.3% | -19.3% |
| Operating Income | (42.41M) | 3.64M | (71.21M) | (40.49M) | (4.44M) |
| Operating Margin | -4.7% | 0.3% | -3.6% | -1.6% | -0.2% |
| Interest Income | 407K | 1.37M | 5.26M | 5.54M | 4.19M |
| Interest Expense | 25.43M | 15.57M | 54.21M | 24.72M | 57.47M |
| Other Income / Expenses | 12.61M | (65.72M) | (131.19M) | (22.55M) | (530.2M) |
| Income Before Tax | (29.8M) | (62.08M) | (202.41M) | (63.04M) | (534.64M) |
| Pre-Tax Margin | -3.3% | -4.6% | -10.3% | -2.5% | -28.5% |
| Income Tax Expense | 483K | (43.38M) | (89.37M) | (1.41M) | (126K) |
| Net Income | (37.6M) | (19.16M) | (113.04M) | (61.62M) | (534.51M) |
| Net Margin | -4.1% | -1.4% | -5.8% | -2.4% | -28.5% |
| EPS (Basic) | (0.36) | (0.20) | (1.28) | (0.81) | (5.07) |
| EPS (Diluted) | (0.36) | (0.20) | (1.28) | (0.81) | (5.07) |
| Weighted Avg Shares | 86.07M | 93.7M | 111.25M | 114.68M | 114.21M |
| Weighted Avg Shares (Diluted) | 86.07M | 93.7M | 111.25M | 114.68M | 114.21M |
Evolent Health, Inc.
NYSE:EVH
Intrinsic Alpha fair value
Locked
Current Price
$3.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.